We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Influence of daily aspirin therapy on ACE2 expression and function—implications for SARS‐CoV‐2 and patients with aspirin‐exacerbated respiratory disease.
- Authors
Buchheit, Kathleen M.; Hacker, Jonathan J.; Gakpo, Deborah H.; Mullur, Jyotsna; Sohail, Aaqib; Laidlaw, Tanya M.
- Abstract
Plasma levels of ACE2, Ang-I, Ang-II, Ang(1-7) and Ang(1-9) were detectable in most samples (Figure 1, A-F), though only Ang(1-7) was consistently detectable in nasal fluid (Figure 1, E). Keywords: ACE2; Aspirin; aspirin-exacerbated respiratory disease; asthma; COVID-19; NSAID; SARS-CoV-2; TMPRSS2 EN ACE2 Aspirin aspirin-exacerbated respiratory disease asthma COVID-19 NSAID SARS-CoV-2 TMPRSS2 968 971 4 06/30/21 20210701 NES 210701 Key Messages Daily aspirin does not change nasal expression of ACE2 or TMPRSS2 or alter levels of angiotensin-derived peptides in patients with AERD or aspirin-tolerant asthma, suggesting that its use is unlikely to increase risk of severe SARS-CoV-2 infection. ACE2, Aspirin, aspirin-exacerbated respiratory disease, asthma, COVID-19, NSAID, SARS-CoV-2, TMPRSS2.
- Subjects
ANGIOTENSIN converting enzyme; ASPIRIN; SARS-CoV-2; RESPIRATORY diseases; NASAL polyps
- Publication
Clinical & Experimental Allergy, 2021, Vol 51, Issue 7, p968
- ISSN
0954-7894
- Publication type
Article
- DOI
10.1111/cea.13898